We have long known that improvements in medication adherence are the longest lever available to impact wasteful healthcare spending in the United States. We know further that improvements in adherence affect both sides of the value equation in the right direction: improving outcomes and reducing costs. When news broke recently that $3 billion is wasted […]
Here are three things that were absent from the J.P. Morgan 2016 Healthcare Conference in San Francisco last week.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The manufacturers seldom get credit for things they are doing right to the benefit to all concerned.
In healthcare, we have our own Pareto principle: 80% of healthcare costs are attributed to 20% of the populace: the chronically ill.
With high price tags and a tougher path to generic as a biologic, payer pressure on clinicians to raise adherence for PCSK9 drugs to new heights will be keen.
The U.S. healthcare system must expand the network of accountability. Almost all accountability currently lies with physicians.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.